Faropenem medoxomil
- Generic Name
- Faropenem medoxomil
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19NO8S
- CAS Number
- 141702-36-5
- Unique Ingredient Identifier
- 5OK523O4FU
- Background
Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic faropenem. The prodrug form of faropenem offers dramatically improved oral bioavailability and leads to higher systemic concentrations of the drug. Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.
- Indication
Investigated for use/treatment in bacterial infection, bronchitis, otitis media, and pediatric indications.
A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media
Phase 2
Completed
- Conditions
- Otitis Media
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2008-02-08
- Lead Sponsor
- Replidyne
- Target Recruit Count
- 328
- Registration Number
- NCT00276042
- Locations
- 🇮🇱
Local Institution, Beer Sheva, Israel
A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2008-06-03
- Lead Sponsor
- Replidyne
- Target Recruit Count
- 491
- Registration Number
- NCT00255983
- Locations
- 🇺🇸
Multicenter, New Hope, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath